145 related articles for article (PubMed ID: 33375770)
1. Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
Damnernsawad A; Bottomly D; Kurtz SE; Eide CA; McWeeney SK; Tyner JW; Nechiporuk T
Haematologica; 2022 Jan; 107(1):77-85. PubMed ID: 33375770
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.
Urbino I; Secreto C; Apolito V; Olivi M; Arrigo G; Boscaro E; Catania FM; D'Ardia S; Frairia C; Giai V; Freilone R; Bruno B; Lanzarone G; Giaccone L; Busca A; Dellacasa CM; Ferrero D; Audisio E; Cerrano M
Leuk Res; 2024 Jan; 136():107421. PubMed ID: 38042648
[No Abstract] [Full Text] [Related]
3. [Correlation of
Wang LY; Jiang PF; Li JZ; Chen YX; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):395-401. PubMed ID: 38660842
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
Qiu YQ; Zhou J; Kang XS; Shen-Tu JZ; Ding LM; Tan FL; Guo J; Li LJ
Afr J Tradit Complement Altern Med; 2012; 9(3):431-9. PubMed ID: 23983378
[TBL] [Abstract][Full Text] [Related]
5. Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia.
Modak RV; de Oliveira Rebola KG; McClatchy J; Mohammadhosseini M; Damnernsawad A; Kurtz SE; Eide CA; Wu G; Laderas T; Nechiporuk T; Gritsenko MA; Hansen JR; Hutchinson C; Gosline SJC; Piehowski P; Bottomly D; Short N; Rodland K; McWeeney SK; Tyner JW; Agarwal A
Clin Cancer Res; 2024 May; 30(10):2245-2259. PubMed ID: 38451486
[TBL] [Abstract][Full Text] [Related]
6. Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment.
Pedicona F; Casado P; Hijazi M; Gribben JG; Rouault-Pierre K; Cutillas PR
Sci Signal; 2022 Apr; 15(730):eabl7989. PubMed ID: 35439021
[TBL] [Abstract][Full Text] [Related]
7. [Sorafenib in combination with chemotherapy as induction therapy for FLT3-ITD positive acute myeloid leukemia:nine cases report and literatures review].
Liu S; Wei X; Yin Q; Mi R; Zhang Y; Wang P; Ai H; Zhao H; Han L; Song Y
Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):241-4. PubMed ID: 25854472
[No Abstract] [Full Text] [Related]
8. CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy.
Soares F; Chen B; Lee JB; Ahmed M; Ly D; Tin E; Kang H; Zeng Y; Akhtar N; Minden MD; He HH; Zhang L
Blood; 2021 Apr; 137(16):2171-2181. PubMed ID: 33270841
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2.
Xu X; Ma W; Qiu G; Xuan L; He C; Zhang T; Wang J; Liu Q
Biology (Basel); 2023 Oct; 12(10):. PubMed ID: 37887047
[TBL] [Abstract][Full Text] [Related]
10. Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation.
Wang E; Zhou H; Nadorp B; Cayanan G; Chen X; Yeaton AH; Nomikou S; Witkowski MT; Narang S; Kloetgen A; Thandapani P; Ravn-Boess N; Tsirigos A; Aifantis I
Cell Stem Cell; 2021 Apr; 28(4):718-731.e6. PubMed ID: 33450187
[TBL] [Abstract][Full Text] [Related]
11. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon.
Zhu Y; Zhang D; Shukla P; Jung YH; Malgulwar PB; Chagani S; Colic M; Benjamin S; Copland JA; Tan L; Lorenzi PL; Javle M; Huse JT; Roszik J; Hart T; Kwong LN
JCI Insight; 2024 Jan; 9(2):. PubMed ID: 38060314
[TBL] [Abstract][Full Text] [Related]
12. RAS MAPK inhibitors deregulation in leukemia.
Pasmant E; Vidaud D; Ballerini P
Oncoscience; 2015; 2(12):930-1. PubMed ID: 26909356
[No Abstract] [Full Text] [Related]
13. Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma.
Costacurta M; Vervoort SJ; Hogg SJ; Martin BP; Johnstone RW; Shortt J
Haematologica; 2021 Jul; 106(7):2013-2017. PubMed ID: 33375771
[TBL] [Abstract][Full Text] [Related]
14. High-Throughput CRISPR Screening Identifies Genes Involved in Macrophage Viability and Inflammatory Pathways.
Covarrubias S; Vollmers AC; Capili A; Boettcher M; Shulkin A; Correa MR; Halasz H; Robinson EK; O'Briain L; Vollmers C; Blau J; Katzman S; McManus MT; Carpenter S
Cell Rep; 2020 Dec; 33(13):108541. PubMed ID: 33378675
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.
Mosquera Orgueira A; Peleteiro Raíndo A; Cid López M; Antelo Rodríguez B; Díaz Arias JÁ; Ferreiro Ferro R; Alonso Vence N; Bendaña López Á; Abuín Blanco A; Bao Pérez L; Melero Valentín P; González Pérez MS; Cerchione C; Martinelli G; Montesinos Fernández P; Pérez Encinas MM; Bello López JL
PLoS One; 2021; 16(2):e0247093. PubMed ID: 33592069
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.
Yuan W; Tao R; Huang D; Yan W; Shen G; Ning Q
Aging (Albany NY); 2021 Jan; 13(3):3969-3993. PubMed ID: 33495404
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma.
Yang XD; Kong FE; Qi L; Lin JX; Yan Q; Loong JHC; Xi SY; Zhao Y; Zhang Y; Yuan YF; Ma NF; Ma S; Guan XY; Liu M
Mol Cancer; 2021 Jan; 20(1):20. PubMed ID: 33485358
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy for
Burchert A
Haematologica; 2021 Mar; 106(3):664-670. PubMed ID: 33472354
[TBL] [Abstract][Full Text] [Related]
19. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock LK; Dolnik A; Cocciardi S; Sträng E; Theis F; Jahn N; Panina E; Blätte TJ; Herzig J; Skambraks S; Rücker FG; Gaidzik VI; Paschka P; Fiedler W; Salih HR; Wulf G; Schroeder T; Lübbert M; Schlenk RF; Thol F; Heuser M; Larson RA; Ganser A; Stunnenberg HG; Minucci S; Stone RM; Bloomfield CD; Döhner H; Döhner K; Bullinger L
Blood; 2021 Jun; 137(22):3093-3104. PubMed ID: 33598693
[TBL] [Abstract][Full Text] [Related]
20. A genome-wide CRISPR/Cas9 screen in acute myeloid leukemia cells identifies regulators of TAK-243 sensitivity.
Barghout SH; Aman A; Nouri K; Blatman Z; Arevalo K; Thomas GE; MacLean N; Hurren R; Ketela T; Saini M; Abohawya M; Kiyota T; Al-Awar R; Schimmer AD
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33476303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
